公开(公告)号：WO2022266034A1

公开(公告)日：2022-12-22

申请号：PCT/US2022/033337

申请日：2022-06-14

Applicant: ABBOTT LABORATORIES ,  MCQUISTON, Beth ,  DATWYLER, Saul ,  MARINO, Jaime

Inventor： MCQUISTON, Beth ,  DATWYLER, Saul ,  MARINO, Jaime

IPC: G01N33/53 ,  G01N33/68

Abstract: Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as mild, moderate, severe, or moderate to severe traumatic brain injury (TBI) by detecting levels of a biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject (e.g., a human subject) that has or may have sustained an injury or suspected injury to the head that is caused or believed to have been caused by acoustic energy, electromagnetic energy (e.g., from a sonic weapon, a directed energy weapon or a combination thereof), an over pressurization wave, blast wind, or any combination thereof.

公开(公告)号：WO2022119841A1

公开(公告)日：2022-06-09

申请号：PCT/US2021/061215

申请日：2021-11-30

Applicant: ABBOTT LABORATORIES

Inventor： MCQUISTON, Beth ,  DATWYLER, Saul

IPC: G01N33/68

Abstract: Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.

公开(公告)号：WO2018067474A1

公开(公告)日：2018-04-12

申请号：PCT/US2017/054787

申请日：2017-10-02

Applicant: ABBOTT LABORATORIES

Inventor： DATWYLER, Saul ,  MCQUISTON, Beth ,  BRATE, Elaine ,  RAMP, John ,  PACENTI, David

IPC: G01N33/573

Abstract: Disclosed herein are improved methods of assessing Glial fibrillary acidic protein (GFAP) status in a subject (such as for examples, as a measure of traumatic brain injury or for other clinical reasons).

Abstract translation: 本文公开了评估受试者中胶质纤维酸性蛋白（GFAP）状态的改进方法（例如，作为创伤性脑损伤或其他临床原因的量度）。

公开(公告)号：WO2019112860A1

公开(公告)日：2019-06-13

申请号：PCT/US2018/062888

申请日：2018-11-28

Applicant: ABBOTT LABORATORIES

Inventor： MCQUISTON, Beth ,  DATWYLER, Saul ,  CHANDRAN, Raj ,  MARINO, Jaime

IPC: G01N33/68

Abstract: Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject that has sustained or may have sustained an injury to the head. For example, the present disclosure provides methods for aiding in the diagnosis and evaluation of a subject to determine whether the subject has sustained a traumatic brain injury (TBI) by detecting or measuring a combination of the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in samples taken at various time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：WO2018222784A1

公开(公告)日：2018-12-06

申请号：PCT/US2018/035232

申请日：2018-05-30

Applicant: ABBOTT LABORATORIES ,  MCQUISTON, Beth ,  KORLEY, Frederick ,  BESHIRI, Agim ,  MARINO, Jaime ,  DATWYLER, Saul

Inventor： MCQUISTON, Beth ,  KORLEY, Frederick ,  BESHIRI, Agim ,  MARINO, Jaime ,  DATWYLER, Saul

IPC: G01N33/68

Abstract: Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate, severe, or moderate to severe traumatic brain injury (TBI), using cTnI. Also disclosed are methods for determining whether to perform a head computerized tomography on a subject by detecting levels of cTnI. Finally, also disclosed are methods of outcome in subjects suffering from a mild TBI.

公开(公告)号：WO2018222783A1

公开(公告)日：2018-12-06

申请号：PCT/US2018/035231

申请日：2018-05-30

Applicant: ABBOTT LABORATORIES ,  MCQUISTON, Beth ,  KORLEY, Frederick ,  BESHIRI, Agim ,  MARINO, Jaime ,  DATWYLER, Saul

Inventor： MCQUISTON, Beth ,  KORLEY, Frederick ,  BESHIRI, Agim ,  MARINO, Jaime ,  DATWYLER, Saul

IPC: G01N33/68

Abstract: Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or a moderate, severe, or moderate to severe traumatic brain injury (TBI), by detecting levels of cardiac troponin I (cTnI) and one or more early biomarkers which are not cTnI, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in biological samples taken from a human subject at time points within about 24 hours of injury after the subject has sustained or may have sustained the injury to the head.

公开(公告)号：WO2018200823A1

公开(公告)日：2018-11-01

申请号：PCT/US2018/029585

申请日：2018-04-26

Applicant: ABBOTT LABORATORIES

Inventor： MCQUISTON, Beth ,  ROGERS, Justin ,  DATWYLER, Saul ,  MARINO, Jaime

IPC: G01N33/68

Abstract: Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild, moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting changes of levels of an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a human subject at a time point within about 2 hours, such as about 10, 12, or 20 minutes, after the subject has sustained or may have sustained an injury to the head and a second time point about 3 hours to about 6 hours after the first sample is taken.

公开(公告)号：WO2019113525A3

公开(公告)日：2019-06-13

申请号：PCT/US2018/064587

申请日：2018-12-07

Applicant: ABBOTT LABORATORIES

Inventor： MCQUISTON, Beth ,  DATWYLER, Saul ,  CHANDRAN, Raj

IPC: G01N33/68

Abstract: Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP and/or UCH-L1. These methods involve detecting levels and changes in levels of GFAP and/or UCH-L1 in biological samples taken from a subject at time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：WO2019113525A2

公开(公告)日：2019-06-13

申请号：PCT/US2018/064587

申请日：2018-12-07

Applicant: ABBOTT LABORATORIES

Inventor： MCQUISTON, Beth ,  DATWYLER, Saul ,  CHANDRAN, Raj

IPC: G01N33/68

Abstract: Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP and/or UCH-L1. These methods involve detecting levels and changes in levels of GFAP and/or UCH-L1 in biological samples taken from a subject at time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：WO2018191531A1

公开(公告)日：2018-10-18

申请号：PCT/US2018/027353

申请日：2018-04-12

Applicant: ABBOTT LABORATORIES

Inventor： MCQUISTON, Beth ,  ROGERS, Justin ,  DATWYLER, Saul ,  MARINO, Jaime

IPC: G01N33/68

Abstract: Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting levels of early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a human subject at a time point within about 2 hours, such as about 10, 12, or 20 minutes, after the subject has sustained or may have sustained an injury to the head.